HOME

CalAsia's Mission: CalAsia's mission is to accelerate seminal academic
discoveries into safe and effective treatments for both unmet and under-served medical
needs.

CalAsia's Drug-discovery: CalAsia Pharmaceuticals, Inc. is a privately held early stage pharmaceutical company focused on the rapid discovery of drug-like small molecules through development and execution of its expanding core technologies.

CalAsia's highly sophisticated structure-based design expertise in combination with implementation of a validated and optimized functional screening platform has effectively yielded mature NCEs early in the drug discovery process, thus bypassing the need for traditional high-throughput screening of large compound libraries.

CalAsia also employs an academically-advanced stem cell technology platform to evaluate lead drug candidates for proof of concept using patient-derived human induced pluripotent stem cells (iPSC). This robust technology allows comprehensive in vitro evaluation of late-stage lead compounds in relevant human disease cell-based models prior to transitioning into expensive clinical trials, thus aiding in efficient progression of lead compound development through preclinical stages.

Currently, CalAsia has ongoing drug discovery programs for development of effective treatments that span a multitude of clinical specialties including CNS/Systemic oncology, degenerative CNS disorders, and infectious diseases.

Of note, the CalAsia team has decades of drug discovery experience, including exceptional training and acquired skills in sophisticated structure-based drug design, as evidenced by a prominent history of involvement with numerous successful drug discovery programs, which have produced multiple clinical candidates, as well as one marketed drug.